Business Context and Reporting Period
This Form 8-K was filed by TherapeuticsMD, Inc. on January 9, 2019. The report serves as a Regulation FD disclosure to correct a scrivener's error in an investor presentation originally furnished on January 8, 2019.
Key Financial Metrics
The filing does not provide financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. It focuses exclusively on a correction to a patient dispensing statistic.
Material Changes
The Company corrected the reported number of patients dispensed its product, IMVEXXY, from launch through December 31, 2018:
- Previously Reported: Approximately 21,200 patients.
- Corrected Figure: Approximately 25,500 patients.
Guidance, Outlook, and Risks
The updated slide containing the corrected figure is intended for use in meetings with investors and analysts on January 9, 2019, and subsequently. The filing explicitly states that the information is furnished pursuant to Item 7.01 and is not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, nor is it incorporated by reference into other filings unless expressly stated.
Investor Verification Checklist
- Verify the corrected IMVEXXY patient dispensing count of 25,500 in the updated Exhibit 99.1.
- Confirm that the original January 8, 2019 presentation has been superseded by this update for future investor communications.
- Note that this filing contains no new financial data or forward-looking guidance beyond the statistical correction.